Pitch in New York

Upfront Diagnostics, is proud to announce its selection as one of the presenting companies at the 2025 Columbia, Cambridge, and Oxford Pitch Day. The event will convene top-tier US venture capitalists in New York City.

The company’s CEO, Gonzalo Ladreda, will present their life-saving diagnostic solution, LVOne, to an audience of investors specifically interested in deep-tech, university-originated, VC-backable companies. Upfront Diagnostics is seeking US-centric investors to support its go-to-market strategy in the US.

Upfront Diagnostics’ proprietary technology, which uses a rapid blood test for paramedics to provide crucial information on stroke type in minutes, is aimed at dramatically increasing treatment rates for Large Vessel Occlusion (LVO) strokes.

“We are honoured to be selected for this premier event, which brings the best of UK and US academic innovation to the heart of the US investment community,”

said Gonzalo Ladreda, CEO of Upfront Diagnostics.

“Timely diagnosis is critical for LVO strokes, and our LVOne test is poised to save lives and reduce long-term disability. Connecting with US-centric investors at this stage is vital to accelerating our US market entry.

The selected companies for the pitch day are at the pre-seed, seed, or A stage, and each has raised investment but has not yet raised a formal Series A round. This focus ensures investors meet companies with proven traction and high growth potential. The annual event, which has been hosted by Columbia Technology Ventures since 2017, typically sees over 100 VCs in attendance.

Pitch Day details:

• What: 2025 Columbia, Cambridge, and Oxford Pitch Day

• When: Monday, September 29 2025

• Where: New York Times Building

The pitch will be followed by a Q&A and networking session, providing investors an opportunity for deeper engagement with the Upfront Diagnostics team.

Story by Upfront Diagnostics